Therefore, inhibiting SCF-SKP2 for p27 stabilization recognition may be more beneficial for a therapeutic approach in MPD/CML and other hematological malignancies. This evidence concerns the gene CDKN1B and chronic myelogenous leukemia, BCR-ABL1 positive.